Therefore, a team led by Vladimir Tesar, MD, PhD (Charles University and General University Hospital, in the Czech Republic) tested the
potential of an investigational drug called bosutinib that inhibits a particular tyrosine kinase called Src / Bcr -
Abl.
Together, our data suggest that clinical studies may be warranted to evaluate the therapeutic
potential of
ABL allosteric inhibitors and to determine whether combination therapies that incorporate these compounds are effective in treating metastatic breast cancer.